[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617109":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":11,"centralContacts":31,"locations":37,"responsibleParty":76,"collaborators":11,"id":78,"slug":79,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":11,"eligibilityCriteria":84,"healthyVolunteers":85,"sex":86,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":11,"studyType":92,"phases":93,"briefSummary":95,"conditions":96,"keywords":11,"overallStatus":40,"whyStopped":11,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"Atea Pharmaceuticals, Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"(n=16) buprenorphine\u002Fnaloxone + BEM\u002FRZR","EXPERIMENTAL",null,[13],"Drug: Buprenorphine\u002FNaloxone + BEM\u002FRZR",{"label":15,"type":10,"description":11,"interventionNames":16},"(n=16) methadone + BEM\u002FRZR",[17],"Drug: Methadone +BEM\u002FRZR",[19,26],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Buprenorphine\u002FNaloxone + BEM\u002FRZR","Day -5 to Day -1:buprenorphine\u002Fnaloxone as individualized QD doses up to 24mg\u002F6mg.\n\nDay 1 to Day 5:Individualized QD doses of buprenorphine\u002Fnaloxone. Day 6 to Day 12:Individualized QD doses of buprenorphine\u002Fnaloxone + BEM 550mg\u002FRZR 180mg QD.\n\nDay 13 Individualized QD doses of buprenorphine\u002Fnaloxone.",[9],[25],"BEM (AT-527)\u002FRZR (AT-038)",{"type":20,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"Methadone +BEM\u002FRZR","Day -5 to Day -1:methadone individualized QD doses: 30-150mg. Day 1 to Day 5:Individualized QD does of methadone. Day 6 to Day 12:Individualized QD doses of methadone + BEM 550mg\u002FRZR 180mg QD. Day 13 Individualized QD doses of methadone.",[15],[25],[32],{"name":33,"role":34,"phone":35,"phoneExt":11,"email":36},"Atea Study Clinical Trials Administrator","CONTACT","888-481-1607","ateaclinicaltrials@ateapharma.com",[38,54,65],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Atea Study Site","RECRUITING","Hollywood","Florida","33019","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-80.14949,26.0112,{"lat":50,"lon":49},[53],{"name":33,"role":34,"phone":35,"phoneExt":11,"email":36},{"facility":39,"status":40,"city":55,"state":56,"zip":57,"country":44,"countryCode":45,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"Overland Park","Kansas","66212",{"type":47,"coordinates":59},[60,61],-94.67079,38.98223,{"lat":61,"lon":60},[64],{"name":33,"role":34,"phone":35,"phoneExt":11,"email":36},{"facility":39,"status":40,"city":66,"state":67,"zip":68,"country":44,"countryCode":45,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"Marlton","New Jersey","08053",{"type":47,"coordinates":70},[71,72],-74.92183,39.89122,{"lat":72,"lon":71},[75],{"name":33,"role":34,"phone":35,"phoneExt":11,"email":36},{"type":77,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100617109","phase-1-drug-drug-interaction-study-of-bemnifosbuvirruzasvir-bemrzr-and-buprenorphinenaloxone-or-methadone-100617109",false,"NCT07314346","Drug-drug Interaction Study of Bemnifosbuvir\u002FRuzasvir (BEM\u002FRZR) and Buprenorphine\u002FNaloxone or Methadone","A Phase 1, Open-Label, Two-Part, Single-Sequence Study to Evaluate the Effect of Multiple Oral Doses of BEM\u002FRZR FDC on the Pharmacokinetics of Buprenorphine\u002FNaloxone or Methadone in Participants on Stable Maintenance Therapy for Opiate Withdrawal","Inclusion Criteria:\n\n* Must agree to use acceptable contraceptive methods through at least 90 days after the last dose of study drug.\n* Minimum body weight of 50 kg and body mass index (BMI) of 18-32 kg\u002F m2.\n* Willing to comply with the study requirements and to provide written informed consent.\n\nExclusion Criteria:\n\n* Infected with hepatitis B virus, hepatitis C virus, HIV.\n* Abuse of alcohol or drugs.\n* Use of other investigational drugs within 28 days prior to Day -5.\n* Concomitant use of prescription medications, or systemic over-the-counter medications (apart from methadone or buprenorphine\u002Fnaloxone as assigned maintenance therapy).\n* Other clinically significant medical conditions or laboratory abnormalities.",true,"ALL","18 Years","65 Years",{"count":90,"type":91},32,"ESTIMATED","INTERVENTIONAL",[94],"PHASE1","Drug-drug interaction study between Bemnifosbuvir\u002FRuzasvir (BEM\u002FRZR) and Buprenorphine\u002FNaloxone or Methadone",[97],"Healthy Volunteer Study","2026-04-08",{"date":100,"type":101},"2026-04-13","ACTUAL",{"date":103,"type":101},"2025-01-07",{"date":105,"type":91},"2026-06",{"name":5,"class":6},3]